Botulinum Neurotoxin Type A (BoNT-A) in Paediatric Non-neurogenic Therapy Resistant Overactive Bladder (OAB)

University of Aarhus

Status: Completed

Conditions: Incontinence, Nighttime Urinary; Incontinence, Daytime Urinary; Overactive Bladder

Treatments: Procedure: Intradetrusor BoNT-A

Study type: Observational

Funder types: Other

Identifiers

NCT06569342

OAB-BOTOX

Details and patient eligibility

About

A non-intervention cohort study on the use of Botulinum Neurotoxin Type A (BoNT-A) in Paediatric Non-neurogenic Therapy Resistant Overactive Bladder (OAB). Primary endpoint was the reduction of urinary incontinence.

Full description

The investigators wanted to cunduct an analysis of children with urinary incontinence who received intradetrusor injection of BoNT-A in the period 01.01.2016 to 31.12.2020 at their centre. All patients were refractory to standard urotherapy, anticholinergics, mirabegron and combination of treatments. Patients with neurogenic bladder were excluded.

Primary endpoints were the effect on the frequency of urinary incontinence episodes. Secondary endpoints included urodynamic parameters and uroflow characteristics in relation to side effects and response to treatment.

Enrollment: 43 patients

Sex: All

Ages: 6 to 17 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• OAB
• Intradetrusor BoNT-A

Exclusion criteria

• Neurogenic OAB

Trial design

43 participants in 1 patient group

Main group

Description:

Children with OAB, who underwent intradetrusor BoNT-A-injections

Treatment:

Procedure: Intradetrusor BoNT-A